Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Celldex Therapeutics (CLDX) Return on Assets (2016 - 2025)

Celldex Therapeutics has reported Return on Assets over the past 15 years, most recently at 0.42% for Q4 2025.

  • Quarterly results put Return on Assets at 0.42% for Q4 2025, down 22.0% from a year ago — trailing twelve months through Dec 2025 was 0.42% (down 22.0% YoY), and the annual figure for FY2025 was 0.38%, down 13.0%.
  • Return on Assets for Q4 2025 was 0.42% at Celldex Therapeutics, down from 0.33% in the prior quarter.
  • Over the last five years, Return on Assets for CLDX hit a ceiling of 0.16% in Q4 2021 and a floor of 0.43% in Q3 2023.
  • Median Return on Assets over the past 5 years was 0.28% (2022), compared with a mean of 0.28%.
  • Biggest five-year swings in Return on Assets: increased 25bps in 2024 and later decreased -22bps in 2025.
  • Celldex Therapeutics' Return on Assets stood at 0.16% in 2021, then tumbled by -100bps to 0.31% in 2022, then dropped by -22bps to 0.38% in 2023, then surged by 48bps to 0.2% in 2024, then plummeted by -115bps to 0.42% in 2025.
  • The last three reported values for Return on Assets were 0.42% (Q4 2025), 0.33% (Q3 2025), and 0.28% (Q2 2025) per Business Quant data.